Effects of a Smartphone‐Enabled, Physician‐Supervised Treat‐to‐Target Model for Gout Management: A 12‐Month Randomized Controlled Trial
Primary result · Proportion of patients achieving SUA <360μmol/LResult — go to the resultRisk ratio 1.75 95% CI 1.46–2.10Authors' conclusion
An integrated, physician-supervised, digitally supported T2T care model significantly improved SUA target attainment and reduced gout flares compared with usual care over 12 months. Multi-center trials will be needed to fully evaluate the generalizability, cost-effectiveness, and optimal configuration of this approach.
Study context
- Population
- Men with goutmen with gout enrolled
- Participants
- 280 men
- Comparison
- Integrated, smartphone-enabled, physician-supervised treat-to-target (T2T) care model vs usual care
- App-Led Caren = 140
- Usual Caren = 140reference
- Primary endpoint
- Proportion of patients achieving SUA <360μmol/L
- Follow-up
- 12 months
Primary result
As reported in the abstract
Risk ratio
1.75
95% CI 1.46–2.10
P < 0.0001
Events by treatment group
App-Led Carevs Usual Care
risk ratio 1.75 (95% CI 1.46–2.10); P < 0.0001
Secondary outcomes
Annualized gout flare frequency · significantly lower with App-Led Care · secondary outcome
P < 0.01
Exploratory metabolic outcomes: fasting plasma glucose, HbA1c, total cholesterol, LDL cholesterol
- Greater reductions in the App-Led Care group (all P < 0.05)
- Higher medication adherence in the App-Led Care group
- Exploratory
Original publication
Effects of a Smartphone‐Enabled, Physician‐Supervised Treat‐to‐Target Model for Gout Management: A 12‐Month Randomized Controlled Trial. Arthritis Rheumatol. Published 4 November 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →